D C Goff

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:183-94; quiz 147, 273-4. 2005
  2. ncbi Focus on polypharmacy in schizophrenia: does anyone truly benefit?
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Int J Neuropsychopharmacol 7:109-11. 2004
  3. ncbi The treatment of cognitive impairment in schizophrenia
    Donald C Goff
    The Schizophrenia Program, Massachusetts General Hospital and Harvard Medical School, USA
    Pharmacol Biochem Behav 99:245-53. 2011
  4. ncbi A 23-year-old man with schizophrenia
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    JAMA 287:3249-57. 2002
  5. ncbi Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study
    Donald C Goff
    Massachusetts General Hospital, Psychiatry Department, Freedom Trail Clinic, 25 Staniford St, 2nd Floor, Boston, MA 02114, USA
    Schizophr Res 106:320-7. 2008
  6. ncbi A placebo-controlled study of sildenafil effects on cognition in schizophrenia
    Donald C Goff
    Department of Psychiatry, MGH Schizophrenia Program, Freedom Trail Clinic, Massachusetts General Hospital, Harvard Medical School, 25 Staniford St, 2nd Floor, Boston, MA, 02114, USA
    Psychopharmacology (Berl) 202:411-7. 2009
  7. ncbi A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
    Donald C Goff
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neuropsychopharmacology 33:465-72. 2008
  8. ncbi Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials
    Donald C Goff
    Massachusetts General Hospital, Harvard Medical School, 25 Staniford Street, Boston, MA 02114, USA
    J Clin Psychopharmacol 27:582-9. 2007
  9. ncbi Folate, homocysteine, and negative symptoms in schizophrenia
    Donald C Goff
    Schizophrenia Program and Neurology Service, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 161:1705-8. 2004
  10. ncbi Integrating general health care in private community psychiatry practice
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, USA
    J Clin Psychiatry 68:49-54. 2007

Research Grants

  1. Relapse Prevention: Long-Acting Atypical Antipsychotics
    Donald Goff; Fiscal Year: 2007
  2. Folate in Schizophrenia
    Donald C Goff; Fiscal Year: 2010
  3. Citalopram in First Episode Schizophrenia
    Donald C Goff; Fiscal Year: 2010
  4. Folate in Schizophrenia
    Donald Goff; Fiscal Year: 2009
  5. Folate in Schizophrenia
    Donald Goff; Fiscal Year: 2007
  6. New Treatment and Mechanisms in Schizophrenia
    Donald Goff; Fiscal Year: 2007

Collaborators

Detail Information

Publications97

  1. ncbi Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:183-94; quiz 147, 273-4. 2005
    ..Psychiatrists should address this problem by adopting established strategies for prevention and intervention...
  2. ncbi Focus on polypharmacy in schizophrenia: does anyone truly benefit?
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Int J Neuropsychopharmacol 7:109-11. 2004
  3. ncbi The treatment of cognitive impairment in schizophrenia
    Donald C Goff
    The Schizophrenia Program, Massachusetts General Hospital and Harvard Medical School, USA
    Pharmacol Biochem Behav 99:245-53. 2011
    ..The experience with different pharmacologic targets is reviewed and methodologic issues are discussed with recommendations for future research...
  4. ncbi A 23-year-old man with schizophrenia
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    JAMA 287:3249-57. 2002
  5. ncbi Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study
    Donald C Goff
    Massachusetts General Hospital, Psychiatry Department, Freedom Trail Clinic, 25 Staniford St, 2nd Floor, Boston, MA 02114, USA
    Schizophr Res 106:320-7. 2008
    ..The objective of this exploratory study was to assess whether once-weekly dosing with d-cycloserine will produce persistent improvements in negative symptoms and cognition...
  6. ncbi A placebo-controlled study of sildenafil effects on cognition in schizophrenia
    Donald C Goff
    Department of Psychiatry, MGH Schizophrenia Program, Freedom Trail Clinic, Massachusetts General Hospital, Harvard Medical School, 25 Staniford St, 2nd Floor, Boston, MA, 02114, USA
    Psychopharmacology (Berl) 202:411-7. 2009
    ..In addition, neuronal nitric oxide synthase, another component of the NMDA/nitric oxide/cGMP intracellular pathway, has been reported to be dysregulated in schizophrenia patients...
  7. ncbi A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
    Donald C Goff
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neuropsychopharmacology 33:465-72. 2008
    ..CX516 was not effective for cognition or for symptoms of schizophrenia when added to clozapine, olanzapine, or risperidone...
  8. ncbi Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials
    Donald C Goff
    Massachusetts General Hospital, Harvard Medical School, 25 Staniford Street, Boston, MA 02114, USA
    J Clin Psychopharmacol 27:582-9. 2007
    ..We sought to evaluate the potential role of lamotrigine augmentation in schizophrenia patients resistant to atypical antipsychotic medication...
  9. ncbi Folate, homocysteine, and negative symptoms in schizophrenia
    Donald C Goff
    Schizophrenia Program and Neurology Service, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 161:1705-8. 2004
    ....
  10. ncbi Integrating general health care in private community psychiatry practice
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, USA
    J Clin Psychiatry 68:49-54. 2007
    ....
  11. ncbi A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Mass, USA
    Psychopharmacology (Berl) 179:144-50. 2005
    ..The strongest evidence for efficacy has come from studies using D-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less...
  12. ncbi Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder
    Donald C Goff
    Schizophrenia Program, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychiatry 71:20-6. 2010
    ....
  13. ncbi A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
    Donald C Goff
    Massachusetts General Hospital, Harvard Medical School, Department of Psychiatry 25 Staniford Street, Boston, MA 02114, USA
    Schizophr Res 80:45-53. 2005
    ..The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, despite recent concerns about metabolic complications of certain atypical antipsychotics...
  14. ncbi Pharmacologic implications of neurobiological models of schizophrenia
    Donald C Goff
    Department of Psychiatry, Harvard Medical School, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    Harv Rev Psychiatry 13:352-9. 2005
    ..This article reviews relevant neurodevelopmental, biochemical, and neurodegenerative models with respect to potential pharmacologic opportunities...
  15. ncbi Schizophrenia
    D C Goff
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Med Clin North Am 85:663-89. 2001
    ..Good medical care is as important for the patient with schizophrenia as for any other patient...
  16. ncbi A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
    D C Goff
    Massachusetts General Hospital, Harvard Consolidated Department of Psychiatry, Boston, USA
    Arch Gen Psychiatry 56:21-7. 1999
    ....
  17. ncbi Glutamate in schizophrenia: clinical and research implications
    D C Goff
    Psychotic Disorders Program, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Schizophr Res 27:157-68. 1997
    ..While geriatric patients may be at increased risk for glutamate-mediated neurotoxicity, very little is known about the specific relevance of this model to geriatric patients with schizophrenia...
  18. ncbi D-cycloserine added to clozapine for patients with schizophrenia
    D C Goff
    Psychotic Disorders Program, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 153:1628-30. 1996
    ..The effects of D-cycloserine added to clozapine were assessed and compared with previous results for D-cycloserine plus conventional neuroleptics...
  19. ncbi An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia
    D C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 113:142-7. 2006
    ..We conducted this 6-week open-label trial to examine the effects of adjunctive aripiprazole in clozapine-treated subjects on weight, lipid and glucose metabolism, as well as positive and negative symptoms of schizophrenia...
  20. ncbi A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain
    D C Henderson
    The Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 115:101-5. 2007
    ..This study sought to examine the effectiveness of sibutramine, a weight loss agent, on clozapine-associated weight gain...
  21. ncbi Risperidone added to clozapine: impact on serum prolactin levels
    D C Henderson
    Schizophrenia Research Program, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 62:605-8. 2001
    ..The goal of this study was to determine whether the addition of risperidone to clozapine results in an elevation of serum prolactin levels in patients with chronic schizophrenia or schizoaffective disorder...
  22. ncbi Placebo-controlled trial of glycine added to clozapine in schizophrenia
    A E Evins
    The Psychotic Disorders Unit of the Massachusetts General Hospital, Boston, MA, USA
    Am J Psychiatry 157:826-8. 2000
    ..The purpose of this study was to evaluate the effects of high-dose oral glycine on positive and negative symptoms and cognitive function when added to clozapine in adults with schizophrenia...
  23. ncbi Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
    D C Henderson
    Psychotic Disorders Program, Diabetes Clinical Research Center, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 157:975-81. 2000
    ....
  24. ncbi A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia
    D C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 119:457-65. 2009
    ....
  25. ncbi Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia
    D C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 113:121-5. 2006
    ..We studied a sample of schizophrenia out-patients to test the hypotheses that serum homocysteine concentrations would correlate positively with measures of glucose metabolism...
  26. ncbi High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia
    Michael A Dyer
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States
    Schizophr Res 102:88-95. 2008
    ..In summary, galantamine treatment, at a dose of 32 mg/day, was well tolerated but was not effective as an adjunctive treatment for cognitive deficits in stable nonsmokers with schizophrenia...
  27. ncbi A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004 1150, USA
    J Clin Psychiatry 70:1348-57. 2009
    ..Combining antipsychotics is common practice in the treatment of schizophrenia. This study investigated aripiprazole adjunctive to risperidone or quetiapine for treating schizophrenia and schizoaffective disorder...
  28. ncbi A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia
    D C Goff
    Psychiatry Service, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA
    J Clin Psychopharmacol 21:484-7. 2001
    ..These preliminary results suggest that CX516 and other "ampakines" hold promise for the treatment of schizophrenia...
  29. ncbi The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls
    Ruth S Barr
    The Schizophrenia Program of the Massachusetts General Hospital, Boston, MA 02114, USA
    Neuropsychopharmacology 33:480-90. 2008
    ..These results confirm previous findings that a single dose of nicotine improves attention and suggest that nicotine may specifically improve response inhibition in nonsmokers with schizophrenia...
  30. ncbi Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
    J Clin Psychiatry 70:1674-80. 2009
    ..Clozapine-induced sedation can worsen cognition and impair social and occupational functioning...
  31. ncbi Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychopharmacol 29:165-9. 2009
    ..087). The addition of aripiprazole to a stable dose of olanzapine was well tolerated and resulted in significant improvements on several outcome measures that predict risk for medical morbidity...
  32. ncbi Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight
    Oliver Freudenreich
    MGH Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 65:1372-6. 2004
    ....
  33. ncbi Test-retest reliability of a functional MRI working memory paradigm in normal and schizophrenic subjects
    D S Manoach
    Behavioral Neurology Unit, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Am J Psychiatry 158:955-8. 2001
    ..To interpret the findings, however, it is crucial to know the test-retest reliability of the measures used...
  34. ncbi A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia
    A E Evins
    Harvard Medical School and the Schizophrenia Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Nicotine Tob Res 3:397-403. 2001
    ..These data suggest that bupropion SR, 150 mg/day, combined with CBT, may facilitate smoking reduction in patients with schizophrenia while stabilizing psychiatric symptoms during a quit attempt...
  35. ncbi Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    Hum Psychopharmacol 24:225-32. 2009
    ....
  36. ncbi Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 159:140-6. 2008
    ..Evaluating PTSD in patients with schizophrenia could have important implications from both clinical and research perspectives...
  37. ncbi Increased medial temporal lobe activation during the passive viewing of emotional and neutral facial expressions in schizophrenia
    Daphne J Holt
    Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School, Boston, MA 02129, USA
    Schizophr Res 82:153-62. 2006
    ..Here we tested whether MTL responses to human faces in schizophrenia are abnormal when unconstrained by a cognitive task and measured relative to a low-level baseline (fixation) condition...
  38. ncbi Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia
    Lindsay E Jubelt
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Psychopharmacology (Berl) 199:89-98. 2008
    ..Nicotinic agonists may improve attention and memory in humans and may ameliorate some cognitive deficits associated with neuropsychiatric disorders such as schizophrenia...
  39. ncbi Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study
    David C Henderson
    Schizophrenia Program, MGH Weight Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1116-21. 2005
    ..The goal of this 10-year naturalistic study was to examine, in clozapine-treated patients, the change in cardiovascular risk factors following clozapine initiation and the mortality estimates from cardiovascular disease...
  40. ncbi The emerging role of glutamate in the pathophysiology and treatment of schizophrenia
    D C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 158:1367-77. 2001
    ....
  41. ncbi Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations
    O Freudenreich
    MGH Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 106:323-30. 2002
    ..To review the literature on efficacy and risks of combining antipsychotics (atypical with atypical or conventional) and suggest a rationale and strategies for future clinical trials...
  42. ncbi A single dose of nicotine enhances reward responsiveness in nonsmokers: implications for development of dependence
    Ruth S Barr
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 63:1061-5. 2008
    ..Accumulated evidence suggests that nicotine may increase appetitive responding for nondrug incentives in the environment...
  43. ncbi The inter-trial effects of stimulus and saccadic direction on prosaccades and antisaccades, in controls and schizophrenia patients
    Jason J S Barton
    Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Exp Brain Res 174:487-98. 2006
    ..These results suggest that saccades in humans are modulated by inter-trial effects attributable to both an 'inhibition of return'-like alternation advantage and directional plasticity...
  44. ncbi Distinguishing familiarity-based from source-based memory performance in patients with schizophrenia
    Anthony P Weiss
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Schizophr Res 99:208-17. 2008
    ..Yet the exact nature of these deficits remains a matter of some debate. This study sought to examine performance on two distinct aspects of memory performance: familiarity-based and source-based memory processes...
  45. ncbi Task-switching in schizophrenia: active switching costs and passive carry-over effects in an antisaccade paradigm
    Cathleen Greenzang
    Department of Neurobiology, Harvard College, Cambridge, MA, USA
    Exp Brain Res 181:493-502. 2007
    ..Thus problems with executive control in schizophrenia may not affect specific task-switching operations...
  46. ncbi Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    Biol Psychiatry 51:493-7. 2002
    ....
  47. ncbi Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Arch Gen Psychiatry 62:19-28. 2005
    ....
  48. ncbi Has multiple personality disorder remained consistent over time? A comparison of past and recent cases
    D C Goff
    Psychiatry Service, Massachusetts General Hospital, Boston
    J Nerv Ment Dis 181:595-600; discussion 601-5. 1993
    ..Although a core set of symptoms has consistently been associated with this disorder over time, other important aspects have not been stable...
  49. ncbi Effects of D-cycloserine administration on weekly nonemotional memory tasks in healthy participants
    Michael W Otto
    Boston University, Harvard Medical School, Boston, MA 02215, USA
    Psychother Psychosom 78:49-54. 2009
    ..In this study, we investigated the relative benefit of DCS versus placebo for enhancing nonemotional verbal and nonverbal memory across weekly trials...
  50. ncbi The misattribution of salience in delusional patients with schizophrenia
    Daphne J Holt
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02129, United States
    Schizophr Res 83:247-56. 2006
    ..In this study, we tested the hypothesis that delusional schizophrenia patients are more likely than non-delusional schizophrenia patients and healthy participants to assign affective meanings to neutral stimuli...
  51. ncbi Reduced error-related activation in two anterior cingulate circuits is related to impaired performance in schizophrenia
    Frida E Polli
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02215, USA
    Brain 131:971-86. 2008
    ..Impairments in evaluating and learning from errors in schizophrenia may contribute to behaviour that is rigid and perseverative rather than optimally guided by outcomes, and may compromise performance across a wide range of tasks...
  52. ncbi A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain
    David C Henderson
    Schizophrenia Program, Weight Center, Endocrine Unit, and Biostatistics Center, Massachusetss General Hospital, Boston, USA
    Am J Psychiatry 162:954-62. 2005
    ..This study examined the effectiveness of sibutramine, an approved weight loss agent, in overweight and obese subjects taking olanzapine for schizophrenia or schizoaffective disorder...
  53. ncbi Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia
    X Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital Harvard Medical School Department of Medicine, Massachusetts General Hospital The Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 127:217-26. 2013
    ..All values were expressed as mean ± standard deviation, aripiprazole vs. placebo. Conclusion:  Adjunctive therapy with aripiprazole may have some metabolic benefits in clozapine-treated patients with schizophrenia...
  54. ncbi A failure of sleep-dependent procedural learning in chronic, medicated schizophrenia
    Dara S Manoach
    Department of Psychiatry, Massachusetts General Hospital East, Rm 420, 36 First Avenue, Charlestown, MA 02129, USA
    Biol Psychiatry 56:951-6. 2004
    ..This study tested the hypothesis that patients with schizophrenia have a deficit in sleep-dependent procedural learning...
  55. ncbi Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction
    A Eden Evins
    Harvard Medical School and the Schizophrenia Research Program, Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    J Clin Psychiatry 65:307-11; quiz 452-3. 2004
    ....
  56. ncbi Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, USA
    Schizophr Res 101:273-86. 2008
    ..Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial...
  57. ncbi A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02144, USA
    J Clin Psychopharmacol 27:380-6. 2007
    ....
  58. ncbi Anterior cingulate cortex activation during cognitive interference in schizophrenia
    Stephan Heckers
    Department of Psychiatry, Massachusetts General Hospital, Boston, 02129, USA
    Am J Psychiatry 161:707-15. 2004
    ..Previous studies have reported evidence of structural and functional abnormalities in the anterior cingulate cortex of patients with schizophrenia...
  59. ncbi Ionotropic glutamate receptors as therapeutic targets in schizophrenia
    Joseph T Coyle
    Curr Drug Targets CNS Neurol Disord 1:183-9. 2002
    ..Preliminary results with an allosteric modulator of the AMPA subtype of glutamate receptor suggest enhanced cognitive functions in subjects treated with clozapine...
  60. ncbi Antisaccades and task switching: studies of control processes in saccadic function in normal subjects and schizophrenic patients
    Jason J S Barton
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Ann N Y Acad Sci 956:250-63. 2002
    ..It suggests either carryover inhibition by antisaccadic performance in the prior trial or facilitation of antisaccades by simultaneous performance of other cognitive operations...
  61. ncbi Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA
    Ann Clin Psychiatry 22:33-42. 2010
    ..The goal of this study was to understand the relationship between clozapine and risperidone with glucose and lipid metabolism and dietary fat intake in patients with schizophrenia...
  62. ncbi Schizophrenic subjects show deficient inhibition but intact task switching on saccadic tasks
    Dara S Manoach
    Department of Neurology, Human Vision and Eye Movement Laboratory, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Biol Psychiatry 51:816-26. 2002
    ..We hypothesize that inhibition and task switching are mediated by distinct neural networks, only one of which is dysfunctional in schizophrenia...
  63. ncbi Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages
    Dara S Manoach
    Department of Psychiatry, Massachusetts General Hospital, Charlestown, MA 02129, United States
    J Psychiatr Res 44:112-20. 2010
    ..They provide further evidence that sleep is an important contributor to cognitive deficits in schizophrenia...
  64. ncbi Selective emotional processing deficits to social vignettes in schizophrenia: an ERP study
    Gina R Kuperberg
    Department of Psychology, Tufts University, 490 Boston Avenue, Medford, MA 02155, USA
    Schizophr Bull 37:148-63. 2011
    ..These findings suggest that schizophrenia is associated with a specific neural deficit during the online evaluation of emotionally valent, socially relevant information...
  65. ncbi Family-directed cognitive adaptation for schizophrenia
    Michelle S Friedman-Yakoobian
    Massachusetts Mental Health Center, 180 Morton Street, Jamaica Plain, MA 02130, USA
    J Clin Psychol 65:854-67. 2009
    ..We conclude with a case example of a family who participated in the program...
  66. ncbi D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia
    A Eden Evins
    Harvard Medical School and the Schizophrenia Research Program of the Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    Schizophr Res 56:19-23. 2002
    ..The purpose of this study was to examine the effects of D-cycloserine when added to risperidone on negative symptoms of schizophrenia...
  67. ncbi Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia
    Joshua L Roffman
    Schizophrenia Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, USA
    Schizophr Res 92:181-8. 2007
    ..This study examined whether schizophrenia patients homozygous for the risk allele (T/T) exhibit greater impairment in executive function, and determined the extent to which MTHFR's effects on negative symptoms underlie this relationship...
  68. ncbi Reduced microstructural integrity of the white matter underlying anterior cingulate cortex is associated with increased saccadic latency in schizophrenia
    Dara S Manoach
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02215, USA
    Neuroimage 37:599-610. 2007
    ..Moreover, they suggest that anterior cingulate white matter abnormalities contribute to slower performance of volitional saccades and to inter-individual variability of saccadic latency in chronic, medicated schizophrenia...
  69. ncbi Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia
    A Eden Evins
    Schizophrenia Program, the Tobacco Treatment and Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1184-90. 2005
    ....
  70. ncbi Intact hemispheric specialization for spatial and shape working memory in schizophrenia
    Dara S Manoach
    Department of Psychiatry, Massachusetts General Hospital East, Charlestown, MA 02129, USA
    Schizophr Res 78:1-12. 2005
    ..We hypothesized that reduced specialization in schizophrenia would reflect a failure to adopt optimal domain-specific strategies and would contribute to WM deficits...
  71. ncbi Schizophrenia patients show intact immediate error-related performance adjustments on an antisaccade task
    Frida E Polli
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Schizophr Res 82:191-201. 2006
    ..We examined whether immediate error-related performance adjustments during the antisaccade task were intact in schizophrenia...
  72. ncbi A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 012114, USA
    J Clin Psychopharmacol 25:218-25. 2005
    ..We conclude that bupropion does not worsen clinical symptoms of schizophrenia and is modestly effective for smoking cessation in patients with schizophrenia. The relapse rate is high after treatment discontinuation...
  73. ncbi Dietary intake profile of patients with schizophrenia
    David C Henderson
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA, USA
    Ann Clin Psychiatry 18:99-105. 2006
    ..We performed a cross-sectional study evaluating the dietary intake of patients with schizophrenia or schizoaffective disorder treated with atypical antipsychotic agents...
  74. ncbi Treatment of cardiac risk factors among patients with schizophrenia and diabetes
    Anthony P Weiss
    Department of Psychiatry, Massachusetts General Hospital, Boston, 02114, USA
    Psychiatr Serv 57:1145-52. 2006
    ..The appropriateness and effectiveness of the outpatient medical management of cardiac risk factors for patients with diabetes who had a diagnosis of schizophrenia or a related psychotic syndrome were examined...
  75. ncbi Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Psychiatry Res 149:267-71. 2007
    ..An inflammatory process, as reflected by elevated serum levels of CRP, might be associated with more severe psychopathology in a subgroup of patients with schizophrenia...
  76. ncbi Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St, 2nd Floor, Boston, MA 02114, USA
    Schizophr Res 92:90-4. 2007
    ..Risperidone augmentation of clozapine in refractory schizophrenia has theoretical but only inconsistent support from clinical trials...
  77. ncbi What is perseverated in schizophrenia? Evidence of abnormal response plasticity in the saccadic system
    Jason J S Barton
    Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Abnorm Psychol 114:75-84. 2005
    ..Saccades in schizophrenia are characterized by perseveration of antisaccade-induced changes in the saccadic response system rather than failures to switch task set...
  78. ncbi Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine
    Deborah A Yurgelun-Todd
    Cognitive Neuroimaging Laboratory, Brain Imaging Center, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA
    Psychiatry Res 138:23-31. 2005
    ..These results suggest that the addition of D-cycloserine to conventional neuroleptics may improve negative symptoms through enhanced temporal lobe function...
  79. ncbi Adverse cardiac effects associated with clozapine
    David B Merrill
    New York State Psychiatric Institute, Department of Psychiatry, Columbia University, New York, NY 10032, USA
    J Clin Psychopharmacol 25:32-41. 2005
    ....
  80. ncbi Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia
    Joshua L Roffman
    Schizophrenia Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Biol Psychiatry 63:42-8. 2008
    ..We examined whether the methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C functional polymorphisms contribute to negative symptoms...
  81. ncbi Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial
    Oliver Freudenreich
    MGH Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
    Psychopharmacology (Berl) 181:358-63. 2005
    ..A donepezil add-on strategy might make sense in selected schizophrenia cases where a pathological process is known to affect cholinergic neurons (e.g., history of head injury or comorbid dementia)...
  82. ncbi Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Psychiatr Pract 15:251-61. 2009
    ....
  83. ncbi Insight into current symptoms of schizophrenia. Association with frontal cortical function and affect
    O Freudenreich
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Acta Psychiatr Scand 110:14-20. 2004
    ..Examine whether frontal lobe dysfunction or affective experiences correlates with lack of symptom awareness in schizophrenia...
  84. ncbi Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents
    U Naidoo
    Department of Psychology, Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychoneuroendocrinology 28:97-108. 2003
    ..This potential complication of treatment with certain antipsychotic agents requires careful study and could represent a serious public health problem...
  85. ncbi The potential role of lamotrigine in schizophrenia
    Charles H Large
    Department of Neuropharmacology, Psychiatry CEDD, GlaxoSmithKline SpA, Via Fleming 4, 37135, Verona, Italy
    Psychopharmacology (Berl) 181:415-36. 2005
    ..Furthermore, lamotrigine, which can modulate glutamate release, may add to or synergise with atypical antipsychotic drugs, some of which may themselves modulate glutamate transmission...
  86. ncbi The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome
    Jonathan M Meyer
    VA San Diego Healthcare System, USA
    Schizophr Res 80:9-18. 2005
    ....
  87. ncbi Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status
    Dost Ongur
    Schizophrenia Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Schizophr Res 75:349-62. 2005
    ..To determine the prevalence and clinical significance of obsessive-compulsive (OC) symptoms among a group of stable outpatients with schizophrenia...
  88. ncbi Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III
    Joseph P McEvoy
    Department of Psychiatry and Behavioral Sciences, Duke University, Clinical Research, John Umstead Hospital, 1003 12th Street, Butner, NC 27509, USA
    Schizophr Res 80:19-32. 2005
    ..One important risk factor for cardiovascular disease is the metabolic syndrome (MS), yet limited data exist on its prevalence in US patients with schizophrenia...
  89. ncbi Motor cortical excitability in schizophrenia
    Alvaro Pascual-Leone
    Laboratory for Magnetic Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    Biol Psychiatry 52:24-31. 2002
    ....
  90. ncbi Sustained activation of the hippocampus in response to fearful faces in schizophrenia
    Daphne J Holt
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Biol Psychiatry 57:1011-9. 2005
    ..Using functional magnetic resonance imaging (fMRI), we tested the hypothesis that habituation of the medial temporal lobe is reduced in schizophrenia...
  91. ncbi Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline
    Henry A Nasrallah
    University of Cincinnati, Cincinnati, OH 45267 0559, USA
    Schizophr Res 86:15-22. 2006
    ....
  92. ncbi Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics
    David C Henderson
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Mass, USA
    J Clin Psychiatry 68:533-41. 2007
    ..0-295.9; referred to as "schizophrenia patients" hereafter) treated with atypical antipsychotic agents...
  93. ncbi Polypharmacy in schizophrenia: a fuzzy concept
    Oliver Freudenreich
    J Clin Psychiatry 64:1132; author reply 1132-3. 2003
  94. ncbi Varenicline treatment for smokers with schizophrenia: a case series
    A Eden Evins
    J Clin Psychiatry 69:1016. 2008
  95. ncbi Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, VA San Diego Healthcare System, San Diego, CA 92161, United States
    Schizophr Res 103:104-9. 2008
    ..Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial...
  96. ncbi Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, the Division of Infectious Diseases and Partners AIDS Research Center, and Harvard Medical School, Boston, MA 02114, USA
    Psychosomatics 48:405-11. 2007
    ..However, clinical experience treating HCV in schizophrenia patients is limited; in this cohort, 2 years after screening, no patient had received interferon/ribavirin treatment...
  97. ncbi Sexual functioning, psychopathology and quality of life in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    Schizophr Res 94:119-27. 2007
    ..The present study was to characterize relationships among sexual functioning, schizophrenia symptoms and quality of life measures. In addition, sexual functioning was compared among patients treated with different antipsychotic agents...

Research Grants10

  1. Relapse Prevention: Long-Acting Atypical Antipsychotics
    Donald Goff; Fiscal Year: 2007
    ..Even relatively modest delays in relapse and improvement of long term functioning potentially resulting from a long acting second-generation medication can translate into substantial public health benefits. ..
  2. Folate in Schizophrenia
    Donald C Goff; Fiscal Year: 2010
    ..This will be the first adequately-powered study to assess efficacy and identify predictors of response. ..
  3. Citalopram in First Episode Schizophrenia
    Donald C Goff; Fiscal Year: 2010
    ..In addition, the potential role of SSRI-induced BDNF release in promoting neurogenesis and improving the course of the illness offers an exciting new direction for the pharmacology of schizophrenia. ..
  4. Folate in Schizophrenia
    Donald Goff; Fiscal Year: 2009
    ..This will be the first adequately-powered study to assess efficacy and identify predictors of response. ..
  5. Folate in Schizophrenia
    Donald Goff; Fiscal Year: 2007
    ..This will be the first adequately-powered study to assess efficacy and identify predictors of response. ..
  6. New Treatment and Mechanisms in Schizophrenia
    Donald Goff; Fiscal Year: 2007
    ..Dr. Goff will also continue his mentoring activities as he guides the career development of junior faculty researchers in his group as well as residents and research fellows working on research projects under his direction. ..